On August 1, 2023, Pfizer Inc ($NYSE:PFE). reported their Q2 FY2023 earnings results for the period ending June 30, 2023. Total revenue decreased by 54.1% from last year to USD 12.7 billion, and net income decreased by 76.5% to USD 2.3 billion.
PFIZER INC stock opened at $35.9, however, declined by 1.2% from the previous closing price of 36.1, and eventually closed at $35.6. These results showed a positive trend for PFIZER INC’s financial performance in the second quarter, demonstrating that they are continuing to grow as a company despite the ongoing pandemic. As PFIZER INC continues to adapt to the changing times, they remain committed to delivering quality services and products to their customers and investors alike. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently analyzed the financials of PFIZER INC and gave it a medium risk rating. Our analysis covered a range of factors, including its income sheet and balance sheet. Upon further investigation, we detected two potential risk warnings in the company’s financials. These risk warnings are not visible to the average investor, unless they become a registered user on our platform and conduct a deeper investigation. As a registered user, you can access our advanced financial analysis tools to more accurately identify any risk warnings that may be present. We understand that every investor wants to make informed decisions when investing their hard-earned money. That’s why we strive to provide accurate, up-to-date information to help them make the best decision for their portfolio. At GoodWhale, we believe that knowledge is power and strive to give investors the data and insights they need to make informed decisions. With our comprehensive financial analysis tools, you can trust that your investments are being made with the most accurate and up-to-date information available. More…
Risk Rating Analysis
Star Chart Analysis
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Pfizer Inc, the multinational pharmaceutical company, recently released their FY2023 Q2 earnings results for the period ending June 30 2023, reporting a total revenue of USD 12.7 billion and net income of USD 2.3 billion. This marked a decrease of 54.1% and 76.5% compared to the same period last year, respectively. Additionally, positive progress on their R&D pipeline and a strategy to focus on higher growth areas should also provide some confidence to potential investors. Nevertheless, investors are reminded to conduct an in-depth analysis of their own before making any investment decisions.